|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tool path deformation in 5-axis flank milling using envelope surface 显示文摘 | Lartigue C Duc E Affourd A | 2003 | Computer-Aided Design2003，35，4： | 1 |
| 2 | Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer显示文摘 | LOVE R R DUC N B HAVIGHURST T C | 2003 | J Clin Oncol2003，21，3： | 1 |
| 3 | A New Format for 5- axis Tool Path Computation Using Bspline Curves显示文摘 | Langeron J M Duc E Lartigue C | 2004 | CAD Computer Aided Design2004，36，12： | 1 |
| 4 | A capacitive humidity sensor using cross-linked cellulose acetate butyrate显示文摘 | DucéréV Bernès A Lacabanne C | 2005 | Sensor Actuat B-CHEM2005，106，1： | 1 |
| 5 | Innervation of putative rapidly adapting mechanoreceptors by calbindin - and calretinin-im-munoreactive primary sensory neurons in the rat 显示文摘 | Duc C Brakat - Walter I Droz B | 1994 | Eur Neurosci1994，6，2： | 1 |
| 6 | Avoiding 5-axis singularities using tool path deformation显示文摘 | Affouard A Duc E Lartigue C | 2004 | International Journal of Machine Tools and Manufacture2004，44，4： | 1 |
| 7 | Ellagic compounds from Diplopanax stachyanthus 显示文摘 | Duc D K Sung T V Angela M C | 1990 | Phytochemistry1990，29，1： | 1 |
| 8 | An LMI approach to decentralized H ∞ control 显示文摘 | Scorletti C Duc G | 2001 | International Journal of Control2001，74，3： | 1 |
| 9 | Practical improvements of side-channel attacks on AES:feedback from the 2nd DPA contest显示文摘 | CLAVIER C DANGER J L DUC G | 2014 | Journal of Cryptographic Engineering2014，3，： | 1 |
| 10 | Ellagic compounds from Diplopanax stachyanthus 显示文摘 | Duc D K Sung T V Angela M C | 1990 | Phytochemistry1990，29，1： | 1 |
| 11 | Avoiding 5-axis singularities using tool path deformation 显示文摘 | Affouard A Duc E Lartigue C | 2004 | International Journal of Machine Tools and Manufacture2004，44，4： | 1 |
| 12 | The domain of admissible orientation concept: A new method for five-axis tool path optimization显示文摘 | CASTAGNETTI C DUC E RAY P | 2008 | Computer-Aided Design2008，40，9： | 1 |
| 13 | No Adverse Effect of Genetically Modified Anfifungal Wheat on Decom- position Dynamics and the Soil Fauna Community-A Field Study显示文摘 | Duc C Nentwig W Lindfeld A | 2011 | PLoS One2011，6，25： | 1 |
| 14 | Tetraspanins and malignancy显示文摘 | Boucheix C Duc GH Jasmin C | 2001 | Expert Rev Mol Med2001，3，13： | 1 |
| 15 | An LMI approach to decentralized H∞ control显示文摘 | Scorletti C Duc G | 2001 | Int J Control2001，74，3： | 1 |
| 16 | Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implication for frequent introductions of JEV from Southeast Asia to East Asia显示文摘 | Phan T N Marial del C P Vuong Duc C | 2004 | Gen Virol2004，85，： | 1 |
| 17 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 18 | Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging显示文摘 | Alric C Taleb J Lc Duc G | 2008 | Joumal of the American Chemical Society2008，130，18： | 1 |
| 19 | MicreRNA miR-326 regulates TH-17 differ- entiation and is associated with the pathogenesis of multiple sclerosis 显示文摘 | DuC Liu C Kang J | 2009 | Nat Immuno12009，10，12： | 1 |
| 20 | Bioconversion ofphytosterols to androstanes by mycobacteria growing on sugarcane mud显示文摘 | PEREZ C FALERO A DUC H L | 2006 | J Ind Microbiol Biotechnol2006，148，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员